Senior Director of Clinical Research
HealthTree Foundation
Dr. Jay Hydren, joined HealthTree Foundation to direct the research program aimed at accelerating a cure for Myeloma and to give patients a voice in the scientific literature.
He is in his 15th year performing human based research that spans a large spectrum of research strategies and designs.
His predoctoral fellowship with the US Army Research Institute of Environmental Medicine in Natick, Massachusetts, focused on defining the physical parameters of the common and essential combat arms tasks and developing a set a predictor screening tools that assess candidates likelihood of being able to perform these job tasks, thus being injury free and successful in their military career and creating an objective path for women to join the US Army Combat Arms. A project that after successful implementation has saved us US taxpayers $100 million a year.
His doctoral training focused on age related disease at the University of Utah, where he further studied screening tool development for cardiovascular events, heart attacks and strokes. His biology training intersects with multiple myeloma, thalidomide, a drug that is used to reduce arterial vascular malformation, common in advanced heart failure patients is used to stop critical non-surgical bleeding events, is also the same cellular biological pathway that lead to breakthroughs in multiple myeloma therapy.
Dr. Hydren also worked as a Senior Biostatistician and Business Advisor that focused on bioelectrics to help accelerate physiological adaptation and tissue regeneration. During which he originated the idea to accelerate bone healing for skeletal injuries, which also focused on the same biological pathways that affect bone degeneration for multiple myeloma pathways: RANK / RANK / OPG pathway.
Dr. Hydren over the past year has built out several new research capabilities at HealthTree: quantitative and qualitative research programs, real world-evidence of clinical outcomes and patient reported outcomes.